Apontis Pharma AG (APPH) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.061x

Based on the latest financial reports, Apontis Pharma AG (APPH) has a cash flow conversion efficiency ratio of -0.061x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.94 Million ≈ $-2.27 Million USD) by net assets (€31.62 Million ≈ $36.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Apontis Pharma AG's balance sheet to measure how much of total assets are equity-financed.

Apontis Pharma AG - Cash Flow Conversion Efficiency Trend (2019–2024)

This chart illustrates how Apontis Pharma AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Apontis Pharma AG earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Apontis Pharma AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Apontis Pharma AG ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Buriram Sugar Public Company Limited BK:BRR	0.107x
Zeder Investments Ltd JSE:ZED	0.180x
Sarla Performance Fibers Limited NSE:SARLAPOLY	0.091x
Emerging Display Technologies Corp TW:3038	0.054x
Bionet TWO:1784	0.013x
Sambo Corrugated Board Co. Ltd KQ:023600	0.020x
Sejal Glass Limited NSE:SEJALLTD	0.278x
Bon Fame Co Ltd TWO:8433	0.059x

Annual Cash Flow Conversion Efficiency for Apontis Pharma AG (2019–2024)

The table below shows the annual cash flow conversion efficiency of Apontis Pharma AG from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Apontis Pharma AG stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€31.02 Million ≈ $36.26 Million	€-2.90 Million ≈ $-3.39 Million	-0.094x	+77.54%
2023-12-31	€30.26 Million ≈ $35.38 Million	€-12.60 Million ≈ $-14.73 Million	-0.416x	-257.05%
2022-12-31	€41.57 Million ≈ $48.60 Million	€11.02 Million ≈ $12.88 Million	0.265x	+214.37%
2021-12-31	€40.71 Million ≈ $47.60 Million	€3.43 Million ≈ $4.01 Million	0.084x	-79.90%
2020-12-31	€3.46 Million ≈ $4.04 Million	€1.45 Million ≈ $1.70 Million	0.420x	+917.97%
2019-12-31	€4.64 Million ≈ $5.43 Million	€-238.07K ≈ $-278.33K	-0.051x	--

About Apontis Pharma AG

XETRA:APPH Germany Drug Manufacturers - Specialty & Generic

Market Cap

$107.13 Million

€91.63 Million EUR

Market Cap Rank

#19464 Global

#1794 in Germany

Share Price

€11.00

Change (1 day)

+0.00%

52-Week Range

€10.75 - €11.05

All Time High

€26.90